Clinical trial · Interventional
Biomarkers in Multiple Myeloma
Evaluation of Predictive Biomarkers in de Novo Multiple Myeloma on the Onset of Venous Thromboembolism, Its Impact on Clinical Outcome and Thromboprophylaxis (VESICOM)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Hematological Patients | — | UNRESOLVED | — |
| Newly Diagnosed Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with multiple myeloma
- description
- Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.
- interventionNames
- Other: Blood samples
Primary outcomes (4)
- measure
- Level of thrombin generation in newly diagnosed and untreated MM
- timeFrame
- 24 months
- description
- Measurement of thrombin on plasma from newly diagnosed MM patients before the initiation of chemotherapy
- measure
- Level of factor VIII in newly diagnosed and untreated MM
- timeFrame
- 24 months
- description
- Measurement of factor VIII on plasma from newly diagnosed MM patients before the initiation of chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment. Exclusion Criteria: * Pregnant women * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation * Patient whose follow-up or life expectancy is less than 6 months.
References
Publications (0)
Data not yet available